News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
93,008 Results
Type
Article (10927)
Company Profile (22)
Press Release (82051)
Multimedia
Podcasts (91)
Webinars (12)
Section
Business (35004)
Career Advice (551)
Deals (6041)
Drug Delivery (107)
Drug Development (12951)
Employer Resources (44)
FDA (2045)
Job Trends (2182)
News (51012)
Policy (4907)
Tag
2027 BioCapital Standard (1)
2027 Genetown Standard (3)
2027 Pharm Country Standard (3)
Academia (176)
Accelerated approval (11)
ADA (13)
Adcomms (21)
Allergies (41)
Alliances (8275)
ALS (53)
Alzheimer's disease (344)
Antibody-drug conjugate (ADC) (138)
Approvals (1988)
Artificial intelligence (216)
ASCO (58)
Autoimmune disease (77)
Automation (10)
Bankruptcy (55)
Belgium (1)
Best Places to Work (1213)
BIO (21)
Biologics (3)
BIOSECURE Act (9)
Biosimilars (90)
BioSpace Insights (62)
Biotechnology (13)
Bispecific (2)
Bladder cancer (40)
Brain cancer (11)
Breast cancer (77)
Cancer (1061)
Cardiovascular disease (171)
Career advice (465)
Career pathing (29)
CAR-T (61)
CDC (13)
CDMO (82)
Celiac Disease (1)
Cell-line development (1)
Cell therapy (157)
Cervical cancer (5)
Clinical research (11253)
Collaboration (566)
Commercialization (6)
Company closure (3)
Compensation (126)
Complete response letters (41)
COVID-19 (464)
CRISPR (9)
C-suite (358)
Cystic fibrosis (16)
Data (1077)
Decentralized trials (1)
Denatured (14)
Depression (44)
Dermatology (40)
Diabetes (127)
Diagnostics (555)
Digital health (13)
Diversity (8)
Diversity, equity & inclusion (11)
Drug discovery (135)
Drug pricing (167)
Drug shortages (25)
Duchenne muscular dystrophy (87)
Earnings (10234)
Editorial (51)
Employer branding (6)
Employer resources (50)
Events (12690)
Executive appointments (287)
FDA (2603)
Friedreich's ataxia (2)
Frontotemporal dementia (5)
Funding (376)
Gene editing (30)
Generative AI (38)
Gene therapy (141)
GLP-1 (502)
Government (856)
Grass and pollen (1)
Guidances (47)
Healthcare (1552)
Hematology (24)
HIV (19)
Huntington's disease (23)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (23)
Immunology and inflammation (170)
Immuno-oncology (42)
Indications (23)
Infectious disease (558)
Inflammatory bowel disease (41)
Inflation Reduction Act (6)
Influenza (30)
Intellectual property (47)
Interviews (77)
IPO (2143)
IRA (42)
Job creations (850)
Job search strategy (390)
JPM (40)
Kidney cancer (3)
Kidney disease (20)
Labor market (84)
Layoffs (242)
Leadership (33)
Legal (1140)
Licensing (12)
Liver cancer (20)
Longevity (7)
Lung cancer (152)
Lymphoma (95)
Machine learning (17)
Management (24)
Manufacturing (411)
Marketing (2)
MASH (57)
Medical device (418)
Medtech (425)
Mergers & acquisitions (4105)
Metabolic disorders (598)
mRNA (61)
Multiple sclerosis (43)
NASH (9)
Netherlands (2)
Neurodegenerative disease (115)
Neuropsychiatric disorders (56)
Neuroscience (775)
Neurotech (1)
NextGen: Class of 2026 (646)
Non-profit (150)
Now hiring (58)
Obesity (418)
Opinion (173)
Ovarian cancer (24)
Pain (75)
Pancreatic cancer (63)
Parkinson's disease (74)
Partnered (11)
Patents (134)
Patient recruitment (101)
Peanut (6)
People (10746)
Peptides (1)
Pharmaceutical (12)
Pharmacy benefit managers (22)
Phase 1 (3107)
Phase 2 (5081)
Phase 3 (4390)
Pipeline (1803)
Policy (199)
Postmarket research (291)
Preclinical (1061)
Press Release (4)
Prostate cancer (59)
Psychedelics (34)
Radiopharmaceuticals (92)
Rare diseases (316)
Real estate (979)
Recruiting (22)
Regulatory (4179)
Reports (16)
Research institute (223)
Resumes & cover letters (99)
Rett syndrome (1)
RNA editing (10)
RSV (30)
Schizophrenia (73)
Series A (68)
Series B (46)
Service/supplier (2)
Sickle cell disease (18)
Special edition (23)
Spinal muscular atrophy (46)
Sponsored (9)
Startups (757)
Stomach cancer (10)
Substance use disorders (4)
Supply chain (54)
Tariffs (93)
The Weekly (75)
Vaccines (219)
Venture capital (93)
Weight loss (343)
Women's health (32)
Worklife (10)
Date
Today (15)
Last 7 days (99)
Last 30 days (403)
Last 365 days (4788)
2026 (3589)
2025 (4756)
2024 (5241)
2023 (5754)
2022 (8148)
2021 (7673)
2020 (6711)
2019 (5464)
2018 (4378)
2017 (6196)
2016 (5408)
2015 (5390)
2014 (3334)
2013 (2861)
2012 (2888)
2011 (2852)
2010 (2394)
Location
Africa (186)
Alabama (8)
Arizona (18)
Arkansas (1)
Asia (9617)
Australia (824)
California (1429)
Canada (639)
China (385)
Colorado (92)
Connecticut (135)
Delaware (51)
Europe (21088)
Florida (401)
Georgia (13)
Hawaii (1)
Idaho (3)
Illinois (126)
India (61)
Indiana (63)
Iowa (2)
Japan (230)
Kansas (48)
Kentucky (3)
Louisiana (3)
Maryland (240)
Massachusetts (1211)
Michigan (28)
Minnesota (24)
Mississippi (2)
Missouri (4)
Montana (1)
Nebraska (3)
Nevada (10)
New Hampshire (3)
New Jersey (835)
New Mexico (16)
New York (409)
North Carolina (208)
Northern California (585)
Ohio (74)
Oklahoma (1)
Oregon (7)
Pennsylvania (429)
Puerto Rico (20)
Rhode Island (8)
South America (237)
South Carolina (3)
Southern California (697)
Tennessee (18)
Texas (142)
United States (5956)
Utah (22)
Virginia (25)
Washington D.C. (19)
Washington State (197)
West Virginia (1)
Wisconsin (16)
Wyoming (1)
93,008 Results for "biohaven pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Biohaven could get up to $795M in epilepsy alliance with SK Bio
At the center of Biohaven’s agreement with SK Biopharmaceutical is the ion channel platform and the lead epilepsy candidate opakalim, for which Phase 2/3 data are expected later this year.
August 26, 2026
·
2 min read
·
Tristan Manalac
FDA
Biohaven takes another hit as FDA pauses enrollment in pivotal trials for embattled epilepsy drug
The enrollment pause comes after BHV-7000 failed to show efficacy in a midstage depression trial late last year. The news is another regulatory hit for Biohaven after the FDA declined to approve its spinocerebellar ataxia treatment in November 2025.
September 10, 2026
·
3 min read
·
Heather McKenzie
Obesity
Biohaven looks to obesity to bounce back from run of clinical and regulatory failures
After trial flops in spinal muscular atrophy, depression and bipolar disorder—and a costly rare disease drug rejection—Biohaven is undergoing a reset, recasting its former SMA candidate for obesity.
June 1, 2026
·
5 min read
·
Heather McKenzie
Press Releases
Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results
August 10, 2026
·
19 min read
Depression
Biohaven Notches Another Psychiatric Failure Months After Key FDA Rejection
The major depressive disorder failure for BHV-7000 is the drug’s second, after Biohaven’s spinocerebellar ataxia treatment troriluzole was rejected by the FDA in November 2025.
January 2, 2026
·
1 min read
·
Annalee Armstrong
Obesity
JPM26: After a Tough 2025, Biohaven Is Gearing Up To Challenge Goliath—Lilly
Biohaven has suffered a few setbacks in recent months, including an FDA rejection and a missed $150 million benchmark payment, but CEO Vlad Coric looked for the brighter side at JPM, specifically emphasizing a serendipitous discovery that could get the company in the obesity game.
January 20, 2026
·
3 min read
·
Dan Samorodnitsky
Neurodegenerative disease
FDA Delays Decision Date on Biohaven’s Spinocerebellar Ataxia Application
The FDA also changed its tune and is now planning to convene an advisory committee to discuss Biohaven’s application.
May 15, 2025
·
2 min read
·
Tristan Manalac
Funding
Biohaven Seeks $150 Million From Wall Street Following FDA Rejection
After the FDA rejected its spinocerebellar ataxia treatment, Biohaven missed out on a $150 million payment from Oberland Capital. Now the company is reshuffling its pipeline to stay alive.
November 12, 2025
·
3 min read
·
Dan Samorodnitsky
Press Releases
Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results
May 4, 2026
·
13 min read
Rare diseases
Biohaven Cuts R&D Spending by 60% After FDA Rejection of Drug for Rare Neurodegenerative Disease
Biohaven is proposing troriluzole for the treatment of spinocerebellar ataxia, a group of rare, genetic diseases that lead to the progressive loss of control over movement.
November 5, 2025
·
2 min read
·
Tristan Manalac
1 of 9,301
Next
